TEAM
CURRENT MEMBERS
Postdoctoral researchers
Animal-free food safety evaluation
To be completed in 2024
Promoter: Mathieu Vinken
Dr. M. Sci. Miloš Mihajlović
Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury
To be completed in 2024
Promoter: Mathieu Vinken
Dr. Pharm. Bruna dos Santos Rodrigues
In vitro and in silico prediction of chemical-induced liver toxicity
To be completed in 2026
Promoter: Mathieu Vinken
Dr. M. Sci. Jian Jiang
Development of a new liver-based in vitro system to detect cholestatic chemicals
To be completed in 2024
Promoter: Mathieu Vinken
Dr. Pharm. Julen Sanz Serrano
In vitro testing of new inhibitors of Cx43 hemichannels and Panx1 channels
To be completed in 2024
Promoter: Mathieu Vinken
Dr. M. Sci. Andrés Tabernilla
In vivo testing of new inhibitors of Cx43 hemichannels and Panx1 channels
To be completed in 2024
Promoter: Mathieu Vinken
Dr. D.V.M. Prashant Kadam
Doctoral researchers
Risk assessment of chemical mixtures: liver toxicity as a case study
To be defended in 2026
Promoters: Mathieu Vinken, Jochem Louisse
Pharm. Ellen Callewaert
Development and in vitro testing of new inhibitors of Cx32 hemichannels and Panx1 channels
To be defended in 2023
Promoters: Mathieu Vinken, Steven Ballet
M. Pharm. Sci. Anne Caufriez
The role of connexins, pannexins and their channels in cholestasis
To be defended in 2022
Promoters: Mathieu Vinken, Pieter Annaert
Pharm. Axelle Cooreman
Effects of microplastics on liver in vitro and in vivo
To be defended in 2025
Promoters: Mathieu Vinken, Lindsey Devisscher
M. Sci. Sybren De Boever
Effects of food supplements on liver in vitro and in vivo
To be defended in 2025
Promoters: Mathieu Vinken, Lindsey Devisscher
Pharm. Amy Maerten
Arne Loosen
Development of new inhibitors of Cx43 hemichannels and Panx1 channels as novel therapeutics for the treatment of liver disease
To be defended in 2022
Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans
Co-promotor: Timo De Groof
Pharm. Raf Van Campenhout
In vitro detection of cholestatic chemicals
To be defended in 2025
Promoter: Mathieu Vinken
Pharm. Jonas van Ertvelde
In vitro detection of steatotic chemicals
To be defended in 2025
Promoters: Mathieu Vinken, Tamara Vanhaecke
Co-promotor: Joery De Kock
Pharm. Anouk Verhoeven
In vitro testing of the hepatotoxic/hepatoprotective potential of herbal medicines and dietary supplements
To be defended in 2026
Promoters: Mathieu Vinken, Hilmi Orhan
Co-promotor: Kristiaan Demeyer
Pharm. Batuhan Yildiz
Technicians
Fien Haenen
Project manager
Dr. Med. Sci. Julia Dominika Zajac
FORMER TEAM MEMBERS
Dr. Alanah Pieters
Dr. Elif Ince Ergüç
Dr. Vânia Vilas-Boas
M. Sci. Emma Arnesdotter
M. Sci. Sara Crespo-Yanguas
M. Sci. Kaat Leroy
Pharm. Eva Gijbels
Pharm. Michaël Maes
Pharm. Joost Willebrords
Miss Ana Rita Coelho Gomes
Miss Dinja De Win
Miss Tâmara Prandini
Miss Tineke Vanhalewyn
Miss Manon Wery
FINISHED POSTDOCTORAL PROJECTS
Role of connexin and pannexin (hemi)channels in liver cancer
Tereza Cristina da Silva: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
Role of connexin and pannexin (hemi)channels in hepatitis
Isabel Veloso Alves Pereira: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury
Vânia Vilas-Boas: completed 31/12/2020
Promoter: Mathieu Vinken
Role of connexin and pannexin (hemi)channels in cholestasis
Alanah Pieters: completed 31/01/2022
Promoter: Mathieu Vinken
Identification of natural inhibitors of pannexin channels
Elif Ince Ergüç: completed 31/01/2023
Promoter: Mathieu Vinken
FINISHED DOCTORAL PROJECTS
Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures
Tatyana Doktorova: defended 16/03/2012
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes
Eva Ramboer: defended 15/10/2015
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
The role of connexins, pannexins and their channels in acute liver failure
Michaël Maes: defended 17/10/2017
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis
Joost Willebrords: defended 29/01/2018
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in liver fibrosis
Sara Crespo Yanguas: defended 25/10/2018
Promoters: Mathieu Vinken, Bruno Cogliati
Connexin43 hemichannels as druggable targets for future anti-seizure medication
Laura Walrave: defended 24/01/2019
Promoter: Ilse Smolders
Co-promoters: Mathieu Vinken, Luc Leybaert
Modelling and prediction of chemical-induced human cholestatic liver injury: a mechanistic approach
Eva Gijbels: defended 01/12/2021
Promoters: Mathieu Vinken, Lindsey Devisscher
Co-promoter: Tamara Vanhaecke
Towards next generation risk assessment of chemicals: liver toxicity as a case study
Emma Arnesdotter: defended 19/05/2022
Promoters: Mathieu Vinken, Tamara Vanhaecke
Role of connexins, pannexins and their channels in liver cancer
Kaat Leroy: defended 31/01/2023
Promoters: Mathieu Vinken, Bruno Cogliati
© 2023 by InVitroTox Consulting.
Proudly created using Wix.com
